Germany’s national genomDE strategy
Andreas Till(University of Bonn), Oliver Kohlbacher(Bernstein Center for Computational Neuroscience Tübingen), Melanie Boerries(University of Freiburg), Tobias B. Haack(Technical University of Munich), Sebastian C. Semler(European Clinical Research Infrastructure Network), Britta Haenisch(Federal Institute for Drugs and Medical Devices), Albrecht Stenzinger(Heidelberg University), Tatjana Huebner(Federal Institute for Drugs and Medical Devices), Christoph Engel(University Hospital Leipzig), Ronald Schwarz(National Association of Statutory Health Insurance Physicians), Evelin Schröck(German Cancer Research Center), Christian Altbürger(Heidelberg University), Malte Spielmann(Christian-Albrechts-Universität zu Kiel), Simon Kreutzfeldt(German Cancer Research Center), Yvonne Möller(University Children's Hospital Tübingen), Michael Krawczak(University Hospital Schleswig-Holstein), Andrea Hahne(Hereditary Disease Foundation), Anna Kron(Düsseldorf University Hospital), Nisar P. Malek(STZ eyetrial), Christian Mertes(Technical University of Munich), Thomas Berlage(Fraunhofer Institute for Applied Information Technology), Olaf Rieß(University of Tübingen), Dieter Beule(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), D. Gómez- Andrés(Federal Ministry of Health), Catharina Scholl(Federal Institute for Drugs and Medical Devices), Ivo Buchhalter(German Cancer Research Center), Heiko Krude(Humboldt-Universität zu Berlin), Peter Schirmacher(Heidelberg University), Rita Schmutzler, Christine Mundlos(DRK Kliniken Berlin), Stephan Ossowski(University of Southern California), Oliver Stegle(German Cancer Research Center), Markus M. Nöthen(University of Bonn), Anna Rasokat(University Hospital Cologne), Jens Bussmann(German Medical Association), Roman A. Siddiqui(European Clinical Research Infrastructure Network), Jürgen Wolf(University of Cologne), Stefan Aretz(University of Bonn), Juliane Friedrichs(Helmholtz Association of German Research Centres), Friedrich von Kessel(European Clinical Research Infrastructure Network), Rudolf Klatt(Federal Institute for Drugs and Medical Devices), Anna Lübbe(Robert Koch Institute), Uwe Lührig(Düsseldorf University Hospital), Luca Pötschke(Federal Institute for Drugs and Medical Devices), Sophia Schade(Federal Ministry of Health), Jana Straßburger(Federal Ministry of Health), Daniel Hübschmann(German Cancer Research Center), Anika Anker(Federal Ministry of Health), Stefan Fröhling(German Cancer Research Center)
Cited by 8
Related Papers
The single-cell transcriptional landscape of mammalian organogenesis
|Nature|2019|4.7k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k